Abstract
Treatment of diabetic neuropathy is still carried out by providing symptomatic therapy, which only improves ± 50% of the total symptoms felt by patients, but does not tackle the underlying causes of the disease. Astaxanthin is a potent antioxidant, anti-inflammatory, and anti-diabetic carotenoid that could be an additional treatment option. We aimed to measure the effectiveness of administering astaxanthin as an additional therapy to improve the impact of pain and discomfort experienced daily by diabetes mellitus patients with painful diabetic neuropathy. We conducted a randomized experimental study with an open label design of 36 patients who had been diagnosed with painful diabetic neuropathy. The control group was treated with standard treatment for painful diabetic neuropathy, and the experimental group was given both standard and additional therapy of astaxanthin at a dose of 6 mg once per day. The impact of pain was assessed using the Brief Pain Inventory (BPI) before administering astaxanthin and on the 4th and 8th weeks after administering astaxanthin. The administration of therapy showed a significant improvement in the impact of pain experienced daily by patients on both treatment groups (p<0.05). However, the mean BPI score of the control and the experimental groups did not differ significantly each week (p>0.05). There is a significant improvement in the BPI of patients with painful diabetic neuropathy who were given additional treatment (add on) of astaxanthin compared to patients who were only given standard treatment for painful diabetic neuropathy.
References
American Diabetes Association. (2014). Diagnosis and Classification of Diabetes Mellitus. Diabetes Care.
Cavan David, Fernandes, J., Makaroff, L., Ogurtsova, K., & Webber, S. (2015). IDF Diabetes Atlas 7th ed. International Diabetes Federation.
CDC. (2020). Diabetes and Your Heart. Centers for Disease Control and Prevention.
Chang, M., & Xiong, F. (2020). Astaxanthin and its Effects in Inflammatory Responses and Inflammation-Associated Diseases: Recent Advances and Future Directions. MDPI, 25.
Davinelli, S., Scapagnini, G., & Nielsen, M. (2018). Astaxanthin in Skin Health, Repair, and Disease: A Comprehensive Review. MDPI.
Forstenpointner, J., Otto, J., & Baron, R. (2018). Individualized neuropathic pain therapy based on phenotyping: are we there yet? The Journal of the International Association for the Study of Pain, 159(3), 569-575.
Jankovic, M., Novakovic, I., Nikolic, D., Maksic, J., Petronic, I., & Cirovic, D. (2021). Genetic and Epigenomic Modifiers of Diabetic Neuropathy. International Journal of Molecular Sciences.
Javed, S., Petropoulos, I., Alam, U., & Malik, R. (2015). Treatment of painful diabetic neuropathy. Therapeutic Advances in Chronic Disease.
Kaur, S., & Pandhi, P. (2011). Painful diabetic neuropathy: an update. Annals of Neurosciences.
Kharroubi, A., & Darwish, H. (2015). Diabetes mellitus: The epidemic of the century. World Journal of DIabetes.
Lin, W.-N., Wen, Y.-T., & Tsai, R.-K. (2018). Neuroprotective effect of astaxanthin in a rat model of anterior ischemic optic neuropathy. Investigative Ophthalmology & Visual Science.
Ministry of Health of the Republic of Indonesia. (2018). Hari Diabetes Sedunia Tahun 2018. Pusat Data dan Informasi Kementerian Kesehatan RI.
Papatheodorou, K. (2018). Complications of Diabetes 2017. Journal of Diabetes Research.
Petrie, J., Guzik, T., & Touyz, R. (2018). Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. The Canadian Journal of Cardiology.
Raputova, J., Srotova, I., Vlckova, E., Sommer, C., Üçeyler, N., & Birklein, F. (2017). Sensory phenotype and risk factors for painful diabetic neuropathy: a cross-sectional observational study. The Journal of the International Association for the Study of Pain, 158(12), 2340-2353.
Singh, J., & Rajbhandari, S. (2014). Pathogenesis of Painful Diabetic Neuropathy. Hindawi Pain Research and Treatment, 2014.
Snyder, M., Gibbs, L., & Lindsay, T. (2016). Treating Painful Diabetic Peripheral Neuropathy: An Update. American Family Physician.
Talukdar, J., Bhadra, B., Dattaroy, T., Nagle, V., & Dasgupta, S. (2020). Potential of natural astaxanthin in alleviating the risk of cytokine storm in COVID-19. Elsevier Public Health Emergency Collection.
Wafa, A., El-Nahas, M., Al-Biaumy, A., & Mansour, Y. (2017). Study of advanced glycation endproducts and their receptors in Egyptian type 2 diabetic individuals with peripheral neuropathy. Egyptian Journal of Obesity, Diabetes, and Endocrinology, 3(1), 15-21.
Wisse, B. (2018). Long-term complications of diabetes. U.S. National Library of Medicine.
Recommended Citation
Pinzon, Rizaldy Taslim and Budi Harsana, Mary Rose Angelina
(2021)
"The Benefits of Astaxanthin to Improve Pain Relief in Patients with Painful Diabetic Neuropathy: An Open-Label, Randomized Controlled Trial,"
Pharmaceutical Sciences and Research: Vol. 8:
No.
3, Article 3.
DOI: 10.7454/psr.v8i3.1217
Available at:
https://scholarhub.ui.ac.id/psr/vol8/iss3/3
Included in
Alternative and Complementary Medicine Commons, Chemical and Pharmacologic Phenomena Commons, Medical Neurobiology Commons, Medicinal Chemistry and Pharmaceutics Commons, Natural Products Chemistry and Pharmacognosy Commons, Neurosciences Commons, Organic Chemicals Commons, Other Chemicals and Drugs Commons, Other Neuroscience and Neurobiology Commons, Other Pharmacy and Pharmaceutical Sciences Commons, Pharmaceutics and Drug Design Commons, Pharmacology Commons
